We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Solo titulares de alta señal — eventos macro, earnings, M&A, regulación. Listicles y clickbait de analistas filtrados por defecto. Refrescado cada hora.
Shares of Novo Nordisk (NVO), the maker of the GLP-1 drug Wegovy, popped this morning after the company reported strong demand for its new weight-loss pill.Novo Nordisk President & CEO Mike Doustdar joined Julie Hyman on Opening Bid to discuss Q1 sales and the rest of the year guidance.
Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in Chi
The Danish drugmaker is riding a wave of peptide craziness as its weight loss tablet crushes its U.S. debut.
Strong demand but earnings fall short
Novo Nordisk (NYSE:NVO) reported first-quarter results that far exceeded analyst estimates on Wednesday, driven by surging demand for its oral weight-loss pill and strong international sales. Net sales reached $15.2 billion in the quarter, well above the $11.2 billion analysts had...
Beyond obvious strength in Healthcare, we're starting to see "green shoots" in industries that a year ago were seeing negative growth.
Novo Nordisk shares climbed Wednesday after the Danish drugmaker beat estimates with its latest quarterly results.
Strong Wegovy demand lifted revenue as earnings missed estimates
Novo Nordisk stock jumped early Wednesday on a strong first-quarter report on the back of its GLP-1 drugs Wegovy and Ozempic.
News of the day for May 6, 2026
Find insight on Novo Nordisk, Hartalega, Smith & Nephew and more in the latest Market Talks covering Health Care.
First-quarter sales of the oral Wegovy pill hit $353 million, more than double analyst expectations, as the company lifted its full-year outlook
Novo Nordisk (NYSE:NVO) raised its full-year guidance on Wednesday, citing continued strong demand for its obesity and diabetes treatments despite softer underlying first-quarter results caused by pricing pressure. The pharmaceutical group said it now expects adjusted sales and operating profit for 2026 to decline between 4% and 12% at constant exchange rates, representing a narrower contraction than previously anticipated and reflecting stronger expectations for its GLP-1 treatment portfolio.
The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.
Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.
Total prescriptions for the new Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.
↗️Advanced Micro Devices (AMD): Shares of the chipmaker soared premarket after it reported stronger sales and logged higher profit. Shares of its peer Super Micro Computer Inc. (SMCI) also jumped premarket.
Shares in Wegovy maker Novo Nordisk surged this morning after it reported strong demand for its new weight-loss pill and upgraded its guidance. The Danish drugmaker said total prescriptions for the Wegovy pill reached around 1.
May 6 (Reuters) - European shares rose on Tuesday, with oil prices dropping and investor optimism rising after U.S.
Total prescriptions for the Wegovy pill reached around 1.3 million in the first quarter and have exceeded 2 million since it launched.
COPENHAGEN, May 6 () - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook for the year was slightly improved. The Danish drugmaker is banking on demand for its new weight-loss pill as competition with U.
VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.
Lilly's Foundayo is off to a strong start, drawing new prescribers and patients as broad pharmacy access and payer coverage fuel early oral obesity momentum.
Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company’s Q1 2026 report. For ... Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show
Competition from Eli Lilly puts pressure on margins despite strong early uptake
Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.
Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...
